Objective: To evaluate the safety and efficacy of 5% imiquimod cream for cutaneous dysplasia in high-risk renal transplant recipients.
Design: A randomized, blinded, placebo-controlled study comparing treated with control skin.
Setting: A specialist organ transplant dermatology clinic.